World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
28082
World Ranking
13175
National Ranking
41

Dae Seog Heo publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Dae Seog Heo sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 610 publications — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Dae Seog Heo D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Dae Seog Heo sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 88 D-Index — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Dae Seog Heo is a researcher affiliated with Seoul National University Hospital in South Korea, with a primary focus in the field of Medicine. Their work spans various subfields, notably Oncology, Pulmonary and Respiratory Medicine, Public Health, Environmental and Occupational Health, Pathology and Forensic Medicine, and Molecular Biology.

The researcher has contributed to several topics centered on cancer and patient care. Key areas of their research include:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Palliative Care and End-of-Life Issues
  • Lymphoma Diagnosis and Treatment
  • Patient Dignity and Privacy
  • Lung Cancer Research Studies
  • Cancer Genomics and Diagnostics

Dae Seog Heo has published extensively, with frequent contributions in specific academic journals and venues. These include:

  • Cancer Research and Treatment
  • Korean Journal of Sports Science
  • Scientific Reports
  • Journal of Korean Medical Science
  • Research Square (Research Square)

Recent papers authored or coauthored by the researcher illustrate the range and focus of their scientific inquiries. Some of these include:

  • "Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment", 2021, Scientific Reports
  • "Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines", 2020, Journal for ImmunoTherapy of Cancer
  • "Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma", 2020, Theranostics
  • "Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma", 2020, Leukemia
  • "Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab", 2021, CHEST Journal

The researcher frequently collaborates with a set of coauthors, reflecting a network of scientific partnerships. Frequent coauthors include:

  • Bhumsuk Keam
  • Tae Min Kim
  • Dong-Wan Kim
  • Miso Kim
  • Shin Hye Yoo

Best Publications

  • Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

    Vincent A. Miller;Vincent A. Miller;Vera Hirsh;Jacques Cadranel;Yuh Min Chen

  • Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

    Sae-Won Han;Tae-You Kim;Pil Gyu Hwang;Soohyun Jeong

  • Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.

    Tae You Kim;Dong-Wan Kim;Jae-Yong Chung;Sang Goo Shin

  • Elevated TGF-β1 Secretion and Down-Modulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients

    June Chul Lee;Kyung Mi Lee;Dong Wan Kim;Dae Seog Heo

  • Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.

    June Koo Lee;Junehawk Lee;Sehui Kim;Soyeon Kim

  • Validation of the Korean version of the EORTC QLQ-C30.

    Y.H. Yun;Y.S. Park;E.S. Lee;S.-M. Bang

  • Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer

    Dong-Wan Kim;Dong-Wan Kim;S. Y. Kim;H. K. Kim;S. W. Kim

  • Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer

    Suresh S. Ramalingam;Fiona Blackhall;Maciej Krzakowski;Carlos H. Barrios

  • Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation

    Sae-Won Han;Tae-You Kim;Yoon Kyung Jeon;Pil Gyu Hwang

  • Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer

    Primo N Lara;Jean Yves Douillard;Kazuhiko Nakagawa;Joachim Von Pawel

  • Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis.

    Bhumsuk Keam;Seock-Ah Im;Kyung-Hun Lee;Sae-Won Han

  • Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer

    Joon Oh Park;Sang-We Kim;Jin Seok Ahn;Cheolwon Suh

  • Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration

    Chan Young Ock;Bhumsuk Keam;Sehui Kim;Ju Seog Lee

  • Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial

    Se Hoon Lee;J. K. Lee;M. J. Ahn;D. W. Kim

  • Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer

    D. Y. Kim;Joo Hang Kim;S. H. Lee;T. Y. Kim

  • Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type

    Tae Min Kim;Tae Min Kim;Yeon Hee Park;Yeon Hee Park;Sang-Yoon Lee;Sang-Yoon Lee;Ji-Hoon Kim;Ji-Hoon Kim

  • Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor.

    Tae Min Kim;Tae Min Kim;Ahnah Song;Dong-Wan Kim;Dong-Wan Kim;Soyeon Kim

  • MicroRNA-146a Downregulates NFκB Activity via Targeting TRAF6 and Functions as a Tumor Suppressor Having Strong Prognostic Implications in NK/T Cell Lymphoma

    Jin Ho Paik;Ji-Young Jang Jang;Yoon Kyung Jeon;Wook Youn Kim

  • Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy-resistant non-small cell lung cancer†

    Sae-Won Han;Pil Gyu Hwang;Doo Hyun Chung;Dong-Wan Kim

  • Elevated TGF-b1 Secretion and Downmodulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients

    June-Chul Lee;Yong-Oon Ahn;Dong-Wan Kim;Dae Seog Heo

Frequent Co-Authors

Dong-Wan Kim
Dong-Wan Kim Seoul National University Hospital
Se-Hoon Lee
Se-Hoon Lee Sungkyunkwan University
Yung-Jue Bang
Yung-Jue Bang Seoul National University
Seock-Ah Im
Seock-Ah Im Seoul National University Hospital
Yoon Kyung Jeon
Yoon Kyung Jeon Seoul National University Hospital
Doo Hyun Chung
Doo Hyun Chung Seoul National University
Young Tae Kim
Young Tae Kim Seoul National University Hospital
Woo Ho Kim
Woo Ho Kim Seoul National University
Dong-Young Noh
Dong-Young Noh Seoul National University
Keunchil Park
Keunchil Park The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine doesn’t always mean becoming a doctor. The United States offers a variety of online degree programs in healthcare fields that can open doors to rewarding roles in medicine. Many students look for the whats the easiest nursing program to get into? as an accessible first step into nursing, providing foundational skills and career mobility.

For those interested in the administrative side of healthcare, online programs are available, such as a healthcare administration associate degree online. This pathway offers fast-track options for entry-level management roles in clinics and hospitals.

Financial assistance is crucial for many students. You can explore medical billing and coding schools that accept fafsa if you’re interested in the technical aspects of healthcare but need help funding your studies.

If standardized exams are a concern, research whether do i need to take the teas test for lpn applies to your desired nursing program—some accredited options have no exam requirements.

Exploring these alternative online healthcare degrees and pathways can help you find the right fit for your interests, budget, and timeline.

Best Scientists Citing Dae Seog Heo

Trending Scientists

Recently Published Articles